Home / Market News / $SLXN

$SLXN news and market catalysts

The 7 most recent market catalysts affecting $SLXN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 2 high impact 0 bullish 4 bearish Biotechnology
Nov 11, 2026 Corporate Catalyst Neutral Impact 65
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
Silexion Therapeutics announced a 1-for-24 reverse share split, a corporate action where the number of outstanding shares is reduced, and the price per share is proportionally incr…
Sep 29, 2026 Corporate Catalyst Neutral Impact 65
Silexion Therapeutics To Raise $837K Via Exercise Of ~3.217M Series E Warrants At $0.2603/Share
Silexion Therapeutics is raising $837,366.36 by having holders of Series E warrants immediately exercise them at a reduced price. While this provides immediate working capital for …
Aug 14, 2026 Corporate Catalyst Bearish Impact 75
Silexion Therapeutics shares are trading lower after the company reported worse-than-expected Q2 results.
The headline indicates a direct negative impact on Silexion Therapeutics (SLXN) due to its poor Q2 earnings. This is a corporate-specific catalyst, but its severity could spill ove…
Aug 14, 2026 Corporate Catalyst Bearish Impact 95
Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (SLXN) announced Q2 EPS of $(5.17), missing the analyst consensus estimate of $(2.12) by a substantial 143.87%. This significant miss indicates that the compa…
Aug 12, 2026 Corporate Catalyst Bearish Impact 85
Silexion Therapeutics shares are trading lower after the company announced the pricing of its $2.5 million public offering of 3,846,161 shares at $0.65 per share.
The public offering by Silexion Therapeutics is a significant corporate catalyst. Pricing new shares at $0.65, likely below the prevailing market price, creates immediate dilution …
Aug 12, 2026 Corporate Catalyst Neutral Impact 55
Reported Earlier, Silexion Therapeutics Prices $2.5M Public Offering Of 3,846,161 Ordinary Shares At $0.65 Per Share
This public offering by Silexion Therapeutics is a moderate corporate catalyst. The primary impact is on SLXN, as the issuance of new shares at $0.65 will dilute existing sharehold…
Aug 4, 2026 Corporate Catalyst Bearish Impact 75
Silexion Therapeutics shares are trading lower after the company announced additional preclinical findings from its ongoing translational immuno-oncology program evaluating SIL204 in human KRAS-mutant cancer cells.
The headline indicates a direct negative impact on Silexion Therapeutics (SLXN) due to preclinical findings from their immuno-oncology program. While the specific details of the 'a…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.